Curanex Pharmaceuticals Advances Phyto-N Drug Development for Ulcerative Colitis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CURX?
Source: Newsfilter
- IND Submission Progress: Curanex Pharmaceuticals is on track to submit an IND for Phyto-N to the FDA in Q4 2026, having completed GMP-compliant pilot production and toxicology studies in Q1, laying a solid foundation for subsequent clinical trials.
- Toxicology Study Results: In March 2026, the company completed a 28-day toxicology study with favorable findings, reporting no significant adverse effects at any dose level, which provides critical data support for future GLP toxicology studies.
- Pipeline Expansion Strategy: Following Q1, Curanex expanded its pipeline to include cancer cachexia, a market projected to reach approximately $3.9 billion by 2033, demonstrating the company's strategic vision in addressing significant unmet medical needs.
- Strong Financial Position: As of March 31, 2026, Curanex reported approximately $4 million in cash and cash equivalents, which is sufficient to support key development activities for Phyto-N, including toxicology and manufacturing, ensuring stable funding for future R&D efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CURX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CURX
About CURX
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Curanex Pharmaceuticals Advances Phyto-N Drug Development for Ulcerative Colitis
- IND Submission Progress: Curanex Pharmaceuticals is on track to submit an IND for Phyto-N to the FDA in Q4 2026, having completed GMP-compliant pilot production and toxicology studies in Q1, laying a solid foundation for subsequent clinical trials.
- Toxicology Study Results: In March 2026, the company completed a 28-day toxicology study with favorable findings, reporting no significant adverse effects at any dose level, which provides critical data support for future GLP toxicology studies.
- Pipeline Expansion Strategy: Following Q1, Curanex expanded its pipeline to include cancer cachexia, a market projected to reach approximately $3.9 billion by 2033, demonstrating the company's strategic vision in addressing significant unmet medical needs.
- Strong Financial Position: As of March 31, 2026, Curanex reported approximately $4 million in cash and cash equivalents, which is sufficient to support key development activities for Phyto-N, including toxicology and manufacturing, ensuring stable funding for future R&D efforts.
See More
Curanex Pharmaceuticals Under Investigation for Potential Securities Fraud
- Securities Fraud Investigation: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud and other unlawful business practices involving Curanex Pharmaceuticals Inc., which may significantly impact shareholder rights and necessitate investor vigilance regarding legal repercussions.
- IPO Details: Curanex conducted its Initial Public Offering on August 26, 2025, selling 3.75 million shares at $4.00 each, raising a total of $15 million, indicating initial market confidence in its botanical drug development efforts.
- Severe Stock Volatility: Following the IPO, Curanex's stock peaked at $9.16 per share on September 16, 2025, but was halted the next day due to extreme volatility, plummeting to $1.51 per share on a trading volume of 26 million shares, highlighting significant market instability.
- Legal Expertise: Wolf Haldenstein has extensive experience in prosecuting securities class actions and derivative litigation, having been repeatedly appointed by courts to major roles in complex securities multi-district and consolidated litigation, underscoring its capability in protecting investor interests.
See More
Investigation into Potential Securities Fraud at Curanex Pharmaceuticals
- Securities Fraud Investigation: Wolf Haldenstein Adler Freeman & Herz LLP has announced an investigation into potential securities fraud involving Curanex Pharmaceuticals and its executives, aimed at protecting shareholder interests and pursuing possible legal claims.
- IPO Details: Curanex conducted its Initial Public Offering on August 26, 2025, selling 3.75 million shares at $4.00 each, raising $15 million, indicating initial success in capital markets despite subsequent challenges.
- Stock Price Volatility: Following the IPO, Curanex's stock peaked at $9.16 per share on September 16, 2025, but plummeted to $1.51 by the close on September 17 due to extreme volatility, with a trading volume of 26 million shares, highlighting market instability.
- Law Firm Expertise: Wolf Haldenstein has extensive experience in securities class actions and derivative litigation, having been repeatedly appointed by courts to major roles in complex securities multi-district and consolidated litigation, underscoring its expertise and influence in such cases.
See More
Schall Law Firm Investigates Curanex for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Curanex Pharmaceuticals Inc, focusing on whether the company issued false or misleading statements that could affect investor rights.
- Legal Compliance Issues: The investigation aims to determine if Curanex failed to disclose information pertinent to investors, potentially leading to shareholder losses and damaging the company's reputation.
- Investor Rights Protection: Schall encourages affected shareholders to participate in the investigation and offers free consultations, demonstrating a commitment to safeguarding investor rights.
- Securities Litigation Expertise: As a firm specializing in securities class action lawsuits, Schall's investigation may provide legal support for affected investors, enhancing their confidence in the market.
See More
Curanex Pharmaceuticals Stock Rises 6% on Positive Patient Case Study for Phyto-N
- Patient Case Study: Curanex Pharmaceuticals Inc. highlighted a compelling case involving a pancreatic neuroendocrine tumor patient, demonstrating significant improvements after one month on Phyto-N, including increased energy, abdominal pain resolution, and normalized complexion, underscoring the product's potential efficacy.
- Biomarker Improvements: Laboratory tests confirmed that the patient's serum amylase, lipase, and triglycerides returned to normal ranges, indicating Phyto-N's positive impact on physiological conditions, which could offer new treatment options for cancer patients.
- Market Opportunity: Curanex views cancer cachexia as a multi-billion-dollar market opportunity, with no FDA-approved therapies currently available; Phyto-N is positioned to play a crucial role in enhancing quality of life and maintaining cancer treatment, as emphasized by CEO Jun Liu.
- Future Development Plans: Curanex is advancing Phyto-N through preclinical studies in preparation for an IND submission for ulcerative colitis in 2026, while also exploring broader supportive care opportunities in oncology, reflecting the company's strategic focus on future market potential.
See More
Curanex Highlights Potential of Phyto-N in Cancer Cachexia Treatment
- Patient Case Study: Curanex Pharmaceuticals highlights a patient case from Memorial Sloan Kettering Cancer Center, demonstrating the potential efficacy of its drug Phyto-N in cancer cachexia, with the patient reporting significant improvements in energy and quality of life within one month of use.
- Biomarker Improvement: Following Phyto-N treatment, laboratory tests indicated substantial improvements in pancreatic biomarkers, with serum amylase decreasing from 191 to 90 and serum lipase from 298 to 52, both returning to normal ranges, suggesting a positive impact on cancer-related cachexia.
- Market Demand and Strategic Significance: Cancer cachexia affects up to 80% of advanced cancer patients, and Curanex believes that therapies aiding in weight maintenance and quality of life are clinically significant, especially given the lack of effective treatment options currently available.
- Future Development Focus: Curanex is expanding its strategic focus to include cancer cachexia treatment, with plans for an Investigational New Drug submission in Q4 2026, reflecting the company's commitment to addressing this significant unmet medical need.
See More
Curanex Pharmaceuticals Advances Phyto-N Drug Development for Ulcerative Colitis
- IND Submission Progress: Curanex Pharmaceuticals is on track to submit an IND for Phyto-N to the FDA in Q4 2026, having completed GMP-compliant pilot production and toxicology studies in Q1, laying a solid foundation for subsequent clinical trials.
- Toxicology Study Results: In March 2026, the company completed a 28-day toxicology study with favorable findings, reporting no significant adverse effects at any dose level, which provides critical data support for future GLP toxicology studies.
- Pipeline Expansion Strategy: Following Q1, Curanex expanded its pipeline to include cancer cachexia, a market projected to reach approximately $3.9 billion by 2033, demonstrating the company's strategic vision in addressing significant unmet medical needs.
- Strong Financial Position: As of March 31, 2026, Curanex reported approximately $4 million in cash and cash equivalents, which is sufficient to support key development activities for Phyto-N, including toxicology and manufacturing, ensuring stable funding for future R&D efforts.
See More
Curanex Pharmaceuticals Under Investigation for Potential Securities Fraud
- Securities Fraud Investigation: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud and other unlawful business practices involving Curanex Pharmaceuticals Inc., which may significantly impact shareholder rights and necessitate investor vigilance regarding legal repercussions.
- IPO Details: Curanex conducted its Initial Public Offering on August 26, 2025, selling 3.75 million shares at $4.00 each, raising a total of $15 million, indicating initial market confidence in its botanical drug development efforts.
- Severe Stock Volatility: Following the IPO, Curanex's stock peaked at $9.16 per share on September 16, 2025, but was halted the next day due to extreme volatility, plummeting to $1.51 per share on a trading volume of 26 million shares, highlighting significant market instability.
- Legal Expertise: Wolf Haldenstein has extensive experience in prosecuting securities class actions and derivative litigation, having been repeatedly appointed by courts to major roles in complex securities multi-district and consolidated litigation, underscoring its capability in protecting investor interests.
See More
Investigation into Potential Securities Fraud at Curanex Pharmaceuticals
- Securities Fraud Investigation: Wolf Haldenstein Adler Freeman & Herz LLP has announced an investigation into potential securities fraud involving Curanex Pharmaceuticals and its executives, aimed at protecting shareholder interests and pursuing possible legal claims.
- IPO Details: Curanex conducted its Initial Public Offering on August 26, 2025, selling 3.75 million shares at $4.00 each, raising $15 million, indicating initial success in capital markets despite subsequent challenges.
- Stock Price Volatility: Following the IPO, Curanex's stock peaked at $9.16 per share on September 16, 2025, but plummeted to $1.51 by the close on September 17 due to extreme volatility, with a trading volume of 26 million shares, highlighting market instability.
- Law Firm Expertise: Wolf Haldenstein has extensive experience in securities class actions and derivative litigation, having been repeatedly appointed by courts to major roles in complex securities multi-district and consolidated litigation, underscoring its expertise and influence in such cases.
See More
Schall Law Firm Investigates Curanex for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Curanex Pharmaceuticals Inc, focusing on whether the company issued false or misleading statements that could affect investor rights.
- Legal Compliance Issues: The investigation aims to determine if Curanex failed to disclose information pertinent to investors, potentially leading to shareholder losses and damaging the company's reputation.
- Investor Rights Protection: Schall encourages affected shareholders to participate in the investigation and offers free consultations, demonstrating a commitment to safeguarding investor rights.
- Securities Litigation Expertise: As a firm specializing in securities class action lawsuits, Schall's investigation may provide legal support for affected investors, enhancing their confidence in the market.
See More
Curanex Pharmaceuticals Stock Rises 6% on Positive Patient Case Study for Phyto-N
- Patient Case Study: Curanex Pharmaceuticals Inc. highlighted a compelling case involving a pancreatic neuroendocrine tumor patient, demonstrating significant improvements after one month on Phyto-N, including increased energy, abdominal pain resolution, and normalized complexion, underscoring the product's potential efficacy.
- Biomarker Improvements: Laboratory tests confirmed that the patient's serum amylase, lipase, and triglycerides returned to normal ranges, indicating Phyto-N's positive impact on physiological conditions, which could offer new treatment options for cancer patients.
- Market Opportunity: Curanex views cancer cachexia as a multi-billion-dollar market opportunity, with no FDA-approved therapies currently available; Phyto-N is positioned to play a crucial role in enhancing quality of life and maintaining cancer treatment, as emphasized by CEO Jun Liu.
- Future Development Plans: Curanex is advancing Phyto-N through preclinical studies in preparation for an IND submission for ulcerative colitis in 2026, while also exploring broader supportive care opportunities in oncology, reflecting the company's strategic focus on future market potential.
See More
Curanex Highlights Potential of Phyto-N in Cancer Cachexia Treatment
- Patient Case Study: Curanex Pharmaceuticals highlights a patient case from Memorial Sloan Kettering Cancer Center, demonstrating the potential efficacy of its drug Phyto-N in cancer cachexia, with the patient reporting significant improvements in energy and quality of life within one month of use.
- Biomarker Improvement: Following Phyto-N treatment, laboratory tests indicated substantial improvements in pancreatic biomarkers, with serum amylase decreasing from 191 to 90 and serum lipase from 298 to 52, both returning to normal ranges, suggesting a positive impact on cancer-related cachexia.
- Market Demand and Strategic Significance: Cancer cachexia affects up to 80% of advanced cancer patients, and Curanex believes that therapies aiding in weight maintenance and quality of life are clinically significant, especially given the lack of effective treatment options currently available.
- Future Development Focus: Curanex is expanding its strategic focus to include cancer cachexia treatment, with plans for an Investigational New Drug submission in Q4 2026, reflecting the company's commitment to addressing this significant unmet medical need.
See More
